Ana Aparicio is an associate professor at MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology, who specializes in the treatment of advanced prostate cancer. Her clinical and translational research focuses on the development of novel therapies for a subset of aggressive prostate cancer. Through a series of prospective clinical trials and parallel studies in preclinical models, she defined a molecular signature for this subset and has shown that it predicts treatment resistance. This work serves as the foundation for a much-needed biologically-based, clinically-relevant molecular classification of prostate cancer that will increase the efficiency of clinical and translational research, permit effective and individualized treatment strategies for the lethal variants, and spare patients unnecessary treatments.